Targeting Biofilms in Translational Research, Device Development, and Industrial Sectors

<div>​Overview and data in biofilm sectors: why targeting biofilms is necessary, Dustin Williams</div><div><br></div><div>Impact of biofilms in orthopaedics as they relate to regulatory requirements and needs to be met, David Armbruster, MS, MSE, R&D Group Manager, DePuy Synthes</div><div><br></div><div>Clinical problems of biofilm implant-related infection and methods/need to target biofilms in patients, Javad Parvizi, MD, Professor of Orthopaedic Surgery, Rothman Institute at Thomas Jefferson University Hospital</div><div><br></div><div>Impact of biofilms in catheter systems and regulatory considerations,</div><div><br></div><div>Bryan Haymond, MBA, Product Manager, Bard Access Systems</div><div><br></div><div>Potential benefits of targeting biofilms in wound-related and other tissue infections, Garth James, PhD, Associate Research Professor, Center for Biofilm Engineering, Montana State University</div><div><br></div><div>Biofilms, prevalence and problems related to injured sold</div>iers and military healthcare facilities, COL Clinton K. Murray, MD, FACP, FIDSA, Colonel, US Army<div><br></div><div>FDA insight into the biofilm problem and regulatory management strategy for medical devices, K. Scott Phillips, PhD, Biofilms Research Group Leader, The US FDA and CDR US Public Health Service</div><div><br></div><div>Benefits of standardizing approaches to assessing antimicrobial efficacies against biofilms for industrial applications, Darla Goeres, PhD, Associate Research Professor, Chemical & Biological Engineering, Standards Biofilm Methods Laboratory, Center for Biofilm Engineering, Montana State University</div><div><br></div><div>EPA insight in the biofilm problem and regulatory management strategy for industrial sectors, Steve Tomasino, PhD, Senior Scientist, Environmental Protection Agency</div>